Repros Therapeutics (RPRX) Earning Favorable Press Coverage, Report Shows
News articles about Repros Therapeutics (NASDAQ:RPRX) have been trending positive on Friday, according to Alpha One. The research firm, a subsidiary of Accern, scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repros Therapeutics earned a media sentiment score of 0.26 on Alpha One’s scale. Alpha One also assigned media coverage about the biotechnology company an impact score of 95 out of 100, indicating that recent news coverage is extremely likely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Alpha One’s analysis:
- Somewhat Favorable News Coverage Extremely Likely to Impact Repros Therapeutics (RPRX) Share Price (americanbankingnews.com)
- REPROS THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K) (4-traders.com)
- Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions (finance.yahoo.com)
- Technical Roundup On Two Stocks – Verint Systems Inc. (VRNT), Repros Therapeutics Inc. (RPRX) – Post Analyst (postanalyst.com)
Separately, S&P Equity Research raised their price target on shares of Repros Therapeutics from $1.22 to $1.50 in a research note on Monday, January 30th.
Shares of Repros Therapeutics (NASDAQ:RPRX) traded down 1.98% on Friday, reaching $0.99. 404,836 shares of the company were exchanged. The stock has a 50 day moving average of $1.17 and a 200-day moving average of $1.46. Repros Therapeutics has a 52-week low of $0.93 and a 52-week high of $2.97. The company’s market capitalization is $26.41 million.
Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Friday, March 31st. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Repros Therapeutics had a negative net margin of 39,128.00% and a negative return on equity of 151.63%. The firm earned $0.01 million during the quarter. On average, analysts predict that Repros Therapeutics will post ($0.61) EPS for the current fiscal year.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Stock Ratings for Repros Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc and related stocks with our FREE daily email newsletter.